Get started
Adaptimmune Therapeutics plcAA

Adaptimmune Therapeutics plc

0.2711USDR
−0.0092−3.28%
Last update at 20:45 GMT
USD
No tradesPost-market
See on Supercharts
Overview
Financials
News Ideas Discussions Technicals Forecast Seasonals Options

ADAP fundamentals

Key facts

Market capitalization‪72.28 M‬USD
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)−0.27USD
Founded2014
Employees (FY)506
CEOAdrian Rawcliffe
Websiteadaptimmune.com
About

Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. Its clinical pipeline includes Afami-cel, Lete-cel, and ADP-A2M4CD8. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

Ownership
‪‪257.85 M‬‬
Free Float shares
‪‪228.64 M‬‬ (88.67%)
Closely held shares
‪‪29.21 M‬‬ (11.33%)
Free Float shares
‪‪228.64 M‬‬ (88.67%)
Closely held shares
‪‪29.21 M‬‬ (11.33%)
Capital structure
Market cap
‪‪72.28 M‬‬
Debt
‪‪48.71 M‬‬
Cash & equivalents
‪‪59.56 M‬‬
Enterprise value
‪‪61.42 M‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪72.28 M‬‬
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
0.40x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
0.40x
Valuation ratios
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪6.00‬
‪12.00‬
‪18.00‬
‪24.00‬
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−2,400.0%‬
‪−1,600.0%‬
‪−800.0%‬
‪0.0%‬
‪800.0%‬
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪‪−140.00 M‬‬
‪‪−70.00 M‬‬
‪0.00‬
‪‪70.00 M‬‬
‪‪140.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−51.00 M‬‬
‪‪−34.00 M‬‬
‪‪−17.00 M‬‬
‪0.00‬
‪‪17.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−48.00 M‬‬
‪‪−32.00 M‬‬
‪‪−16.00 M‬‬
‪0.00‬
‪‪16.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Novel Cell Therapies
TECELRA
By country
Period: 2024
United Kingdom
United States

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
‪0.00‬
‪‪35.00 M‬‬
‪‪70.00 M‬‬
‪‪105.00 M‬‬
‪‪140.00 M‬‬
Actual
Estimate
Earnings
Next:Aug 6, 2025
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
‪−0.12‬
‪−0.08‬
‪−0.04‬
‪0.00‬
‪0.04‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

No dividends
ADAP has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company

Debt level and coverage
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪‪−80.00 M‬‬
‪0.00‬
‪‪80.00 M‬‬
‪‪160.00 M‬‬
‪‪240.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪40.00 M‬‬
‪‪80.00 M‬‬
‪‪120.00 M‬‬
‪‪160.00 M‬‬
Assets
Liabilities